Hancock Jaffe wins OK from ethics committee for FIH VenoValve trial

Hancock Jaffe Laboratories (NSDQ:HJLI) said today that Colombia’s Ethics Committee at Fundación Santa Fe de Bogotá approved a first-in-human trial of its VenoValve bioprosthetic valve.
The Irvine, Calif.-based company’s VenoValve is a porcine valve designed to be implanted into the femoral or popliteal vein to treat lower limb chronic venous insufficiency from damage to leg vein valves after deep vein thrombosis.
Hancock Jaffe said that it is also waiting for approval from the FSFB’s medical research committee to launch the trial, according to a press release.
Last month, the underwriter of an initial public offering by Hancock Jaffe exercised in full its over-allotment option, taking the gross proceeds from the flotation to nearly $9 million.
The post Hancock Jaffe wins OK from ethics committee for FIH VenoValve trial appeared first on MassDevice.

Source: Mass Device - July 24, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Regulatory/Compliance Vascular hancockjaffelabs Source Type: news